SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has sold the commercial rights to its thrombosis business in Europe to US-based Mylan for €641.9m , and will use the funds to further reduce its debt, it announced on Tuesday.
Investors welcomed the news, sending its shares up as much as 9.4% during intraday trading before closing 5.42% up at R141.33. The company has a market capitalisation of R64.5bn.A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »
MARKET WRAP: Shoprite and Aspen boost JSE as miners lag behindThe rand fell to about a one-week low, nearing R17/$, with the JSE all share paring gains following the release of second-quarter GDP data
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »
MARKET WRAP: Shoprite and Aspen boost JSE as miners lag behindThe rand fell to about a one-week low, nearing R17/$, with the JSE all share paring gains following the release of second-quarter GDP data
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »